Previous Close | 8.67 |
Open | 8.80 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 8.80 - 9.24 |
52 Week Range | 7.56 - 23.64 |
Volume | |
Avg. Volume | 292,771 |
Market Cap | 335.713M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.47 |
Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATHA
Athira shareholder Richard Kayne had sent multiple letters to shareholders in recent months slamming the biotech's leadership.
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today issued the following statement in response to Richard A. Kayne’s suspension of his proxy contes
HGF/MET positive modulators reduce pain-related behaviors in a model of diabetic neuropathyBOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve So